Table 1 |. Biologic therapies in development for rheumatic diseases that target the type I interferon pathway.

Treatment name	Type	Targeted rheumatic disease(s)	Phase of testing
Anti-IFNα therapies
Rontalizumab	Humanized anti-IFNα IgG1 mAb	Systemic lupus erythematosus	II
Sifalimumab	Humanized anti-IFNα IgG1 mAb	Systemic lupus erythematosus	II
		Psoriasis	II
		Dermatomyositis and polymyositis	I
AGS-009	Humanized anti-IFNα IgG4 mAb	Systemic lupus erythematosus	I
IFNα Kinoid	IFNα vaccine	Systemic lupus erythematosus	II
		Dermatomyositis	II
Anti-IFNAR therapy
Anifrolumab	Fully human anti-IFNAR mAb	Systemic lupus erythematosus	II/III
		Systemic sclerosis	I
TLR inhibition
NI-0101	Humanized anti-TLR4 mAb	Rheumatoid arthritis	II

IFNAR, type I interferon receptor; mAb, monoclonal antibody; TLR, Toll-like receptor;